Hepatitis C Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight | Major Players: Cocrystal Pharma, Gilead, Merck, BMS, Abbvie, Janssen and others.

Posted on
by

Hepatitis C Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight | Major Players: Cocrystal Pharma, Gilead, Merck, BMS, Abbvie, Janssen and others.
Hepatitis C Market

Hepatitis C is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. It is caused by the hepatitis C virus (HCV) and is a major cause of liver cancer. When the liver is inflamed or damaged, its function can be affected.

 

DelveInsight’s “Hepatitis C Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hepatitis C, historical and forecasted epidemiology as well as the Hepatitis C market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Hepatitis C Market Report:

  • In Japan, as per the research study conducted by Tanaka et al. (2018), the total estimated number of HCV-infected persons, including both diagnosed and undiagnosed carriers, in 2000 was 1,694,954–2,194,954. However, this number decreased to 983,879–1,583,879 in 2011, suggesting the prevalence rate in the range of around 1–2%.
  • France is also a low endemic country for HCV infection and reported prevalence varying from 0.5% to 0.7%. Ozaras and Leblebicioglu (2019) reported a 0.7% prevalence for France. Also, as per Institut Pasteur, in France, the number of HCV seropositive cases is estimated at 400,000, supporting a similar prevalence rate.
  • The World Health Organization (WHO) estimated that in 2019, approximately 290 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer). Of the 58 million persons living with HCV infection globally in 2019, an estimated 21% (15.2 million) knew their diagnosis, and of those diagnosed with chronic HCV infection, around 62% (9.4 million) persons had been treated with DAAs by the end of 2019.
  • According to DelveInsight’s analysis, HCV affects more males than females.
  • In the year 2021, the total prevalent case of HCV was 8,371,844 cases in the 7MM. These cases are expected to grow in the study period 2019–2032.
  • As per the DelveInsight estimates, the US, in 2021, accounted for 3,349,984 prevalent cases (the highest number). These cases are expected to grow in the study period 2019–2032.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/hepatitis-c-market

 

Scope of Hepatitis C Market Report:

  • The report covers the descriptive overview of Hepatitis C, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Hepatitis C epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hepatitis C are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hepatitis C market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hepatitis C market

 

Hepatitis C Pipeline Therapies and Companies:

  • CC-31244: Cocrystal Pharma
  • Vosevi (sofosbuvir, velpatasvir, and voxilaprevir): Gilead Sciences
  • Zepatier (Elbasvir and Grazoprevir): Merck
  • Epclusa (sofosbuvir/velpatasvir): Gilead Sciences
  • Harvoni (ledipasvir and sofosbuvir): Gilead Sciences
  • Daklinza (daclatasvir): Bristal-Myers Squibb
  • Viekira : Abbvie
  • Technivie: Abbvie
  • Sovaldi: Gilead Sciences
  • Olysio: Medivir/Janssen R&D Ireland
  • Viekira : Abbvie
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/hepatitis-c-market

 

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Hepatitis C market
  • To understand the future market competition in the Hepatitis C market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatitis C in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatitis C market
  • To understand the future market competition in the Hepatitis C market

 

Table of contents:

1. Key Insights

2. Executive Summary of Hepatitis C

3. Competitive Intelligence Analysis for Hepatitis C

4. Hepatitis C: Market Overview at a Glance

5. Hepatitis C: Disease Background and Overview

6. Patient Journey

7. Hepatitis C Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Hepatitis C Treatment

11. Marketed Products

12. Emerging Therapies

13. Hepatitis C: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Hepatitis C

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hepatitis-c-market